NURIX THERAPEUTICS, INC. (NRIX) Return on equity 2020–2025
NURIX THERAPEUTICS, INC. (NRIX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-49.1%FY2025 · since FY2020: -14.9% → -49.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -49.1% | -12.4 pp |
| FY2024 | -36.7% | +35.1 pp |
| FY2023 | -71.8% | -12.4 pp |
| FY2022 | -59.4% | -25.2 pp |
| FY2021 | -34.2% | -19.3 pp |
| FY2020 | -14.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More NRIX financial trends
NRIX RevenueNRIX Net incomeNRIX Net marginNRIX Gross profitNRIX Gross marginNRIX Operating incomeNRIX Operating marginNRIX Operating cash flowNRIX Free cash flowNRIX Capital expendituresNRIX Stock buybacksNRIX Dividends paidNRIX Total assetsNRIX Total liabilitiesNRIX Shareholders’ equityNRIX overview →